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Abstract
Background: The NORE1 protein was identified in a yeast two-hybrid screen as a Ras effector
that binds Ras protein in a GTP-dependent manner. NORE1A is a growth and tumour suppressor
that is inactivated in a variety of cancers. In transformed human cells, both full-length NORE1A
protein and its effector domain alone (amino acids 191–363) are localized to microtubules and
centrosomes. However, the mechanism by which NORE1A associates with these cytoskeletal
elements is not known; furthermore, whether centrosomally-associated or microtubule-associated
NORE1A suppresses tumour cell growth has not been yet established.
Findings: We have shown that purified NORE1A fails to bind to microtubules in vitro suggesting
that other protein(s) mediate NORE1A-microtubule association. Using mass-spectrometry, we
identified the Microtubule-Associated Protein 1B (MAP1B) and its homologue C19ORF5 as
NORE1A interaction partners. Suppression of C19ORF5 expression by RNA interference (RNAi)
and immunodepletion of C19ORF5 protein from cell extracts showed that binding of NORE1A to
microtubules is not dependent on C19ORF5. Conversely, RNAi suppression of MAP1B revealed
that MAP1B is required for association of NORE1A with microtubules. RNAi-mediated depletion
of C19ORF5 or MAP1B did not prevent centrosomal localization of NORE1A. Moreover, the
depletion of C19ORF5 or MAP1B did not prevent NORE1A's ability to suppress tumour cell
growth.
Conclusion: The interaction of NORE1A with microtubules is mediated by MAP1B, but not
C19ORF5 protein. Interaction of NORE1A with centrosomes is not dependent on C19ORF5 or
MAP1B, and appears to involve a different mechanism independent of binding to microtubules. The
NORE1A microtubular localization is not required for growth suppression.
Findings
NORE1A interacts with C19ORF5 and MAP1B proteins
We have previously shown that NORE1A associates with
microtubules and that this association is most likely indi-
rect since purified NORE1A cannot efficiently bind to
microtubules assembled from pure tubulin [1]. To iden-
tify proteins that mediate association of NORE1A with
microtubules, we expressed FLAG-tagged full-length
NORE1A or effector domain (amino acids 191–363) in
HEK293 cells and examined NORE1A-bound proteins by
mass spectrometry. Among the most abundant NORE1A
protein partners, we identified two distinct microtubule-
binding proteins: C19ORF5 and MAP1B. The interaction
between ectopically expressed NORE1A and endogenous
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C19ORF5 and MAP1B proteins was confirmed by coim-
munoprecipitation (Figs. 1A–B and 1D).
C19ORF5 interacts with NORE1A but does not mediate its 
binding to microtubules
Both full-length NORE1A and its effector domain alone
are capable of interacting with endogenous C19ORF5
protein in HEK293 cells (Fig. 1A). The N-terminal portion
(amino acids 1–268) and the C-terminal portion (amino
acids 250–416) of NORE1A failed to interact with
C19ORF5 (Fig. 1A), suggesting that the intact effector
domain, amino acids 191–363, mediates NORE1A-
C19ORF5 interaction.
To map the NORE1A-C19ORF5 interaction interface
more precisely, we made several small deletions in the
NORE1A effector domain and tested these proteins for
interaction with C19ORF5. Figure 1C shows that the dele-
tion of amino acids 227–253 completely abolished
NORE1A-C19ORF5 interaction. The smaller deletion
mutant, NORE1A Δ236–253, also failed to interact with
C19ORF5; however, the deletion mutant NORE1A
Δ246–253 retained binding activity. Thus, the region
227–246 within the NORE1A effector domain is respon-
sible for interaction with the C19ORF5 protein.
To determine whether C19ORF5 protein is required for
the interaction of NORE1A with microtubules, we first
depleted endogenous C19ORF5 protein using RNAi and
examined the interaction of NORE1A with microtubules
in an in vitro cosedimentation assay. Despite significant
RNAi-mediated depletion of the endogenous C19ORF5
protein from HEK293 cells expressing NORE1A, the abil-
ity of NORE1A to interact with microtubules was not
diminished (Fig. 2A). To completely remove C19ORF5,
we immunodepleted the HEK293 cell extract with anti-
C19ORF5 antibody. Purified NORE1A was then added to
immunodepleted or mock-depleted cell extract and the
ability of NORE1A to interact with microtubules was
examined. Figure 2B shows that, despite efficient
C19ORF5 immunodepletion (upper panel), the depleted
cell extract was as capable of mediating NORE1A interac-
tion with microtubules as mock-depleted extract (middle
panel, lanes 1–4). In addition, purified C19ORF5 protein
could not induce interaction of purified NORE1A with
microtubules (Figure 2B, middle panel, lanes 5 and 6),
Interaction of C19ORF5 and MAP1B proteins with wild type and mutant NORE1A Figure 1
Interaction of C19ORF5 and MAP1B proteins with wild type and mutant NORE1A. A-C: HEK293 cells were trans-
fected with FLAG-tagged wild type NORE1A, fragments of NORE1A, or deletion mutants as indicated. Cell lysates were pre-
cipitated for FLAG and the precipitate was probed with antibody against C19ORF5 and MAP1B (upper panels). Lower panels 
show expression of FLAG-tagged proteins in cell extracts. Asterisk denotes NORE1A 1–268 degradation product. D: A549 
cells were infected with retrovirus coding for hrGFP-tagged wild type NORE1A or hrGFP alone as indicated. Cell extracts 
were precipitated for NORE1A and the precipitate was probed with antibody against MAP1B (upper panel). Lower panels 
show expression of NORE1A and MAP1B in cell extracts.BMC Research Notes 2008, 1:13 http://www.biomedcentral.com/1756-0500/1/13
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although the purified C19ORF5 itself interacted strongly
with microtubules (data not shown). The depletion of
C19ORF5 protein using RNA interference in A549 cells
expressing GFP-NORE1A also did not diminish the ability
of GFP-NORE1A to interact with microtubules in vitro
(Fig. 2C).
We have shown previously that full-length NORE1A or its
effector domain, tagged with N terminal GFP, localizes to
microtubules and centrosomes in living A549 cells [1].
We used this cell system combined with RNAi to examine
the role of C19ORF5 in NORE1A intracellular distribu-
tion. Figure 3A upper panel shows that the C19ORF5 pro-
tein was efficiently depleted from A549 cells; importantly,
this depletion has no effect on the GFP-NORE1A abun-
dance (Fig. 3A, lower panel). However, the GFP-NORE1A
associated with microtubules (visualized by α-tubulin
staining) as efficiently in C19ORF5-depleted cells as in
control siRNA-depleted cells (Figure 3B). The colocaliza-
tion was observed in both interphase (Fig. 3B, middle
row) and mitotic (Fig. 3B, bottom row) cells. These results
indicate that C19ORF5 is not required for targeting of
NORE1A to microtubules in vivo.
MAP1B interacts with NORE1A and is required for its 
binding to microtubules
MAP1B is a large (ca. 2500 amino acids) microtubule-
associated protein consisting of several domains. Figures
1B and 1D show that NORE1A and the effector domain
can interact with endogenous MAP1B protein in HEK293
and A549 cells, respectively. Furthermore, interaction
required the intact NORE1A effector domain (amino
acids 191–363) since neither the N-terminal portion (aa
1–268) or the C-terminal portion (aa 250–416) of
NORE1A could interact with MAP1B (Fig. 1B).
To determine whether MAP1B protein mediates the inter-
action of NORE1A with microtubules, we depleted endog-
enous MAP1B from A549 cells by RNAi and examined the
ability of NORE1A or its effector domain to bind to micro-
tubules in vitro. Figure 4A shows that endogenous MAP1B
expression was virtually eliminated by RNAi in A549 cells
and Figure 4B shows that NORE1A was unable to interact
with microtubules in the absence of the MAP1B protein.
To determine whether MAP1B protein is required for tar-
geting of NORE1A to microtubules in living cells, we
examined the distribution of GFP-tagged NORE1A or its
The C19ORF5 protein does not mediate NORE1A binding to microtubules in vitro Figure 2
The C19ORF5 protein does not mediate NORE1A binding to microtubules in vitro. A: C19ORF5 protein was 
depleted by RNA interference in HEK293 cells expressing HA-tagged NORE1A. Equal amounts of cell extracts were probed 
for C19ORF5 (upper panel) or used to examine the ability of NORE1A to bind to microtubules using the microtubule cosedi-
mentation in vitro assay. B: HEK293 cell extract was immunodepleted of the C19ORF5 protein by incubation with 4G1 anti-
body followed by Protein A/G plus agarose, or mock-depleted. Equal amounts of C19ORF5-depleted and mock-depleted 
extracts were probed for C19ORF5 (upper panel). The ability of purified FLAG-NORE1A to interact with microtubules after 
preincubation with C19ORF5-immunodepleted extract (lanes 1–2), mock-immunodepleted extract (lanes 3–4), or purified 
FLAG-C19ORF5 (lanes 5–6) was examined as described in the Methods. C. C19ORF5 protein was depleted by RNA interfer-
ence in A549 cells expressing GFP-tagged NORE1A. Equal amounts of cell extracts were probed for C19ORF5 (upper panel) 
or used to examine the ability of NORE1A to bind to microtubules as described in Figure 1 (two middle panels). Lower panel, 
the ability of GFP moiety, expressed alone in A549 cells, to bind to microtubules was examined.BMC Research Notes 2008, 1:13 http://www.biomedcentral.com/1756-0500/1/13
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effector domain in A549 cells in which MAP1B has been
depleted by RNAi. Depletion of MAP1B resulted in loss of
microtubule localization of full-length NORE1A (Figure
4C) and its effector domain, aa 191–363 (See additional
file 1: Supplemental Figure 2). Probing of A549 cell
lysates where MAP1B has been depleted for NORE1A
indicated that the NORE1A level was not changed, ruling
out the effect of MAP1B on NORE1A stability (Fig. 4A,
lower panel). Thus, our results indicate that the MAP1B
protein is essential for interaction of NORE1A with micro-
tubules in vitro and in vivo.
The reason why binding of NORE1A to microtubules is
mediated by MAP1B, but not by C19ORF5 is not clear at
the present time. For example, it is possible that the
C19ORF5 protein mediates NORE1A interaction with
microtubules under specific conditions or in specific cell
types not tested here.
The effect of MAP1B or C19ORF5 on centrosomal 
localization of NORE1A
We showed previously that NORE1A is localized to cen-
trosomes in addition to microtubules [1]. This localiza-
tion was observed for endogenous NORE1A, and for
ectopically expressed NORE1A and its effector domain.
Song and co-workers showed that the C19ORF5 protein
was present on centrosomes in interphase and mitotic
HeLa cells [2], while a recent report from the Latif group
described centrosomal localization for C19ORF5 only in
mitotic cells [3]. The MAP1B protein was also detected on
centrosomes in interphase and mitotic cells [4,5]. We
tested whether C19ORF5 or MAP1B play a role in the cen-
trosomal localization of NORE1A.
In A549 cells into which NORE1A was introduced by ret-
roviral-mediated gene transfer, depletion of the C19ORF5
protein did not result in dissociation of NORE1A from
centrosomes in interphase (Fig. 3B, middle row) or
mitotic (Fig. 3B, bottom row) cells. Depletion of MAP1B
protein induced dissociation of full-length NORE1A (Fig.
4C, arrows) and its effector domain (See additional file 1:
Supplemental Figure 3) from microtubules, but not from
centrosomes. Thus, centrosomal localization of NORE1A
is independent of its microtubular localization and does
not require C19ORF5 or MAP1B proteins.
The C19ORF5 protein does not mediate NORE1A binding to microtubules in living cells Figure 3
The C19ORF5 protein does not mediate NORE1A binding to microtubules in living cells. A, B: A549 cells 
expressing GFP-NORE1A were transfected with anti-C19ORF5 siRNA pool or control siRNA as described in the Methods. An 
aliquot of cells was used to examine efficiency of C19ORF5 depletion (A, upper panel) and NORE1A expression level (A, 
lower panel) while other cells growing on coverslip were fixed, processed for immunofluorescence and imaged as described in 
Methods (B). In B, each panel shows NORE1A, microtubules (stained with α-tubulin), centrosomes (stained with pericentrin) 
and a superimposed image. Arrows indicate centrosomes. Bar, 10 μm.BMC Research Notes 2008, 1:13 http://www.biomedcentral.com/1756-0500/1/13
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In contrast to NORE1A, the centrosomal localization of
the closely related tumour suppressor RASSF1A was found
to be dependent on the C19ORF5 protein [2], possibly
reflecting differences in the regulation or mechanisms of
action of NORE1A and RASSF1A. Alternatively, this differ-
ence could be caused by the use of different cell systems:
HeLa cells in ref. [2], compared with A549 cells in this
study.
MAP1B or C19ORF5 are not required for NORE1A to 
suppress tumour cell growth
In an earlier study, we showed that the NORE1A mutant
that was incapable to localize to both centrosomes and
microtubules was deficient in growth suppression [1].
However, the issue whether microtubular localization or
centrosomal localization of NORE1A is required for sup-
pression of tumour cell growth remained unresolved.
Here, we took advantage of the finding that full-length
NORE1A and its effector domain dissociate from microtu-
bules but not from centrosomes upon the MAP1B deple-
tion. In A549 cells into which NORE1A effector domain
was introduced by retroviral-mediated gene transfer,
depletion of the MAP1B protein did not interfere with
NORE1A's ability to suppress growth (Fig. 5A). Likewise,
the depletion of the C19ORF5 protein (Fig. 5B) and the
combined depletion of MAP1B and C19ORF5 (data not
shown) have no effect on NORE1A's induced growth sup-
pression.
Our previous work identified endogenous NORE1A as
centrosomal protein in nontransformed human lung cells
and as a centrosomal and microtubular protein in trans-
formed lung cells [1]. However, this study shows that the
microtubular NORE1A association is not required for its
growth-suppressive activities. This raise the possibility
that it is centrosomal NORE1A that is important for
The MAP1B protein is required for NORE1A binding to microtubules Figure 4
The MAP1B protein is required for NORE1A binding to microtubules. A, B: A549 cells were co-transfected with 
RNA oligos labelled with the Cy3 dye and anti-MAP1B siRNAs or control siRNA. After one day cells were infected with retro-
virus encoding GFP-NORE1A. Two days later, cells were sorted using GFP and Cy3 markers, allowed to recover overnight, 
lysed and equal amounts of cell extract were probed for expression of MAP1B protein (A, upper panel) and GFP-NORE1A 
expression level (A, lower panel). Lysates of GFP and Cy3- positive cells were examined for the ability of GFP-NORE1A to 
interact with microtubules as described in Figure 1 (B). C: A549 cells expressing GFP-NORE1A were transfected with anti-
MAP1B siRNA pool or control siRNA. Cells were fixed, processed for immunofluorescence, and imaged as described in Meth-
ods. Each panel shows NORE1A, microtubules (stained with α-tubulin), centrosomes (stained with pericentrin) and a superim-
posed image. Arrows indicate centrosomes. Bar, 10 μm.BMC Research Notes 2008, 1:13 http://www.biomedcentral.com/1756-0500/1/13
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growth suppression. Further studies are required to deter-
mine the mechanism of NORE1A centrosomal localiza-
tion and the importance of its targeting to centrosomes for
suppression of tumour cell growth.
Reagents
Pools of small-interfering RNA duplexes, cat.# L-016881-
00 against C19ORF5 and cat.# L-010348-00 against
MAP1B were from Dharmacon, Inc. (Lafayette, CO). The
Alexa Fluor 488-labelled AllStars Negative control siRNA,
cat # 1027284, were from Qiagen (Valencia, CA). RNA
duplex labelled with CY3 dye, cat # 4621, were from
Ambion (Austin, TX). The anti-C19ORF5 4G1 antibody
were from A&G Pharmaceutical, Inc. (Columbia, MD).
The monoclonal anti-NORE1A antibody 10F10 was
described in ref [1]. Anti-pericentrin antibody, cat.# ab-
4448, were from Abcam (Cambridge, MA), the anti-α-
tubulin DM-1-A and anti-γ-tubulin GTU-88 antibodies
were from Sigma (St Louis, MO), and the anti-MAP1B
antibody, cat # 612679 was from BD Biosciences. Second-
ary antibody conjugates were from Jackson ImmunoRe-
search (West Grove, PA). All other reagents were
previously described by Moshnikova et al. [1].
Plasmids
Plasmids encoding NORE1A were described previously
[1]. The human C19ORF5 protein (IMAGE clone; ID
5925583) was purchased from ATCC (Manassas, VA) and
subcloned into pCMV5 vector with the N-terminal FLAG
tag. This and all other constructs were prepared using
standard molecular biology techniques [6] and verified by
sequencing.
Cell Lines, Transfection and Retrovirus Production
Cultivation of A549 human lung adenocarcinoma and
HEK293 human embryonic kidney cells (ATCC), HEK293
cells transfection and retroviral supernatants production
was described previously [1,7]. The siRNA duplexes were
transfected using DharmaFECT1 reagent (Dharmacon)
according to the manufacturer's instructions.
Immunodepletion, Immunoprecipitation and Western Blot Analysis
HEK293 cells were lysed in buffer A (30 mM HEPES, pH
7.4, 20 mM KCl, 1mM NaVO4, 20mM NaF, 20 mM β-glyc-
erophosphate, 7.5 mM MgCl2, 1% Triton X-100, 2 mM
EGTA, 0.1% 2-mercaptoethanol and protease inhibitors)
and the C19ORF5 protein was immunodepleted by over-
night incubation with 4G1 antibody adsorbed on Protein
A/G+ beads. The beads were pelleted and the supernatant
was subjected to a second immunodepletion as described
above. For mock immunodepletion, normal mouse IgG
was used instead of anti-C19ORF5 antibody. Other proce-
dures were performed as described previously [1,7].
Immunofluorescent Microscopy and cell preparation
were performed as described previously [1,7]. In some
cases, cells were transfected with siRNA duplexes prior to
plating on coverslips. Forty-eight hours after plating, cells
were fixed in 100% methanol at -20°C for 5 minutes and
processed for immunostaining as described [1]. Digital
images were taken under UV illumination with appropri-
C19ORF5 or MAP1B depletion does not interfere with NORE1A-induced growth suppression Figure 5
C19ORF5 or MAP1B depletion does not interfere with NORE1A-induced growth suppression. A549 cells were 
transfected with anti-MAP1B siRNA pool (A) or control siRNA, or anti-C19ORF5 siRNA pool or control siRNA (B) then 
infected with retrovirus expressing GFP or GFP-NORE1A effector domain (aa 191–363). Two days later, cells were fixed, 
processed for flow cytometry and analyzed as described in Methods. The percentage of GFP-positive cells in each phase of the 
cell cycle +/- mean is shown.BMC Research Notes 2008, 1:13 http://www.biomedcentral.com/1756-0500/1/13
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ate filter sets at 100× magnification using a LEICA
DMIRE2 microscope and captured using IPLab 3.6.5a
software (Scanalytics, Rockville, MD). To allow compari-
son of image intensity within each experiment, images for
GFP-tagged NORE1A and α-tubulin were taken at the
same exposure and processed identically in the Adobe
Photoshop program.
Tubulin-Binding (microtubule cosedimentation in vitro) Assays
Microtubule cosedimentation assay was done with the
Microtubule Binding Protein Spin Down Assay Kit
(Cytoskeleton Inc. Denver, CO, cat.# BK029), according
to the manufacturer's instructions. After assay, the pellet
was adjusted to the same volume as the supernatant with
GTB. Both supernatant and pellet were adjusted to 1 ×
SDS gel loading buffer with 4× stock solution. Equal vol-
umes of supernatant and pellet were separated by SDS
PAGE and analyzed by western blotting. In some experi-
ments, purified FLAG-NORE1A was preincubated for 1
hour at 37°C with C19ORF5-immunodepleted or mock-
immunodepleted HEK293 cell extract, or purified FLAG-
C19ORF5 prior to incubation with microtubules.
Cell Cycle Distribution Assay
A549 cells were transfected with anti-MAP1B siRNA pool,
or anti-C19ORF5 siRNA pool or control siRNA as descried
above. After one day cells were replated in triplicate on 6-
well plates and 8 hours after were infected with retrovirus
expressing GFP or GFP-NORE1A effector domain (aa
191–363). Two days later, cells were fixed with 1% for-
maldehyde in PBS, stained with 0.05 mg/ml propidium
iodide and analyzed by FACSvantage (Becton-Dickinson,
San Jose, CA). Cell cycle distributions of GFP-positive
cells were determined by ModFIT software.
Abbreviations
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4', 6-diamidino-2-phenylindole; GTB, general tubulin
buffer; BSA, bovine serum albumin; kDa, kilodalton;
MAP, microtubule-associated proteins.
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